Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth Gets CLIA OK for Lab

NEW YORK (GenomeWeb News) – MDxHealth today said that it has received CLIA certification for its laboratory in Irvine, Calif.

The Liege, Belgium-based firm also said that the lab has passed inspection by the California Department of Health and is now fully licensed and operational.

MDxHealth plans to offer epigenetic diagnostic products for a number of cancer indications. Its first assay, Prostate ConfirmMDx will be launched in the first half of this year, it said.

"Having our CLIA laboratory operational marks the beginning of our commercial activities in the US, a key driver to our long-term success," MDxHealth CEO Jan Groen said in a statement. "MDxHealth is now well-positioned to introduce its patented epigenetic tests which will aid physicians in the diagnosis and personalized treatment of their patients."

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.